HRP20110348T1 - Imunološke primjene imunomodulatornih spojeva za cjepivo i za liječenje infektivnih bolesti - Google Patents
Imunološke primjene imunomodulatornih spojeva za cjepivo i za liječenje infektivnih bolesti Download PDFInfo
- Publication number
- HRP20110348T1 HRP20110348T1 HR20110348T HRP20110348T HRP20110348T1 HR P20110348 T1 HRP20110348 T1 HR P20110348T1 HR 20110348 T HR20110348 T HR 20110348T HR P20110348 T HRP20110348 T HR P20110348T HR P20110348 T1 HRP20110348 T1 HR P20110348T1
- Authority
- HR
- Croatia
- Prior art keywords
- vaccine
- administration
- compound
- subject
- days
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 19
- 229960005486 vaccine Drugs 0.000 title claims 23
- 201000010099 disease Diseases 0.000 title claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 2
- 230000002924 anti-infective effect Effects 0.000 title 1
- 230000001900 immune effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 230000028993 immune response Effects 0.000 claims abstract 5
- 230000002708 enhancing effect Effects 0.000 claims abstract 2
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 229940023041 peptide vaccine Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract 2
- 239000013566 allergen Substances 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71282305P | 2005-09-01 | 2005-09-01 | |
| PCT/US2006/034271 WO2007028047A2 (en) | 2005-09-01 | 2006-08-31 | Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110348T1 true HRP20110348T1 (hr) | 2011-07-31 |
Family
ID=37806889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110348T HRP20110348T1 (hr) | 2005-09-01 | 2011-05-10 | Imunološke primjene imunomodulatornih spojeva za cjepivo i za liječenje infektivnih bolesti |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8715677B2 (de) |
| EP (2) | EP1928492B1 (de) |
| JP (2) | JP2009507030A (de) |
| AT (1) | ATE499112T1 (de) |
| CA (1) | CA2621136C (de) |
| CY (1) | CY1112325T1 (de) |
| DE (1) | DE602006020300D1 (de) |
| DK (1) | DK1928492T3 (de) |
| ES (2) | ES2359162T3 (de) |
| HR (1) | HRP20110348T1 (de) |
| PL (1) | PL1928492T3 (de) |
| RS (1) | RS51840B (de) |
| SI (1) | SI1928492T1 (de) |
| WO (1) | WO2007028047A2 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090068210A1 (en) * | 2007-07-09 | 2009-03-12 | Munshi Nikhil C | Immunotherapy for hematological malignancies |
| US9200253B1 (en) * | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
| MX347987B (es) | 2007-09-26 | 2017-05-22 | Celgene Corp * | Derivados de quinazolinona 6-,7-, u 8-sustituidos y composiciones que los comprenden y metodos para usar los mismos. |
| US8012466B2 (en) | 2008-01-31 | 2011-09-06 | University Of Iowa Research Foundation | Immunogenic compositions for activating γδ T cells |
| US20090298882A1 (en) * | 2008-05-13 | 2009-12-03 | Muller George W | Thioxoisoindoline compounds and compositions comprising and methods of using the same |
| PT2358697E (pt) | 2008-10-29 | 2016-02-03 | Celgene Corp | Compostos de isoindolina para utilização no tratamento do cancro |
| EP2396312A1 (de) | 2009-02-11 | 2011-12-21 | Celgene Corporation | Lenalidomidisotopologe |
| PT2391355T (pt) | 2009-05-19 | 2017-02-21 | Celgene Corp | Formulações de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolino-1,3-diona |
| EP2516395A1 (de) | 2009-12-22 | 2012-10-31 | Celgene Corporation | (methylsulfonyl)-ethylbenzolisoindolinderivate und ihre therapeutische verwendung |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19177059T1 (de) | 2010-10-01 | 2021-10-07 | Modernatx, Inc. | N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen |
| ES2673114T3 (es) | 2011-01-10 | 2018-06-19 | Celgene Corporation | Derivados de fenetilsulfona isoindolina como inhibidores de PDE 4 y/o citoquinas |
| US9090585B2 (en) | 2011-03-28 | 2015-07-28 | Deuterx, Llc | 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| US20140221427A1 (en) | 2011-06-22 | 2014-08-07 | Celgene Corporation | Isotopologues of pomalidomide |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| KR20140063808A (ko) | 2011-09-14 | 2014-05-27 | 셀진 코포레이션 | 시클로프로판카르복실 산｛２-[(１s)-１-(３-에톡시-４-메톡시-페닐)-２-메탄술포닐-에틸]-３-옥소-２,３-디하이드로-１h-이소인돌-４-일｝-아마이드의 제제 |
| JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
| MX2014007233A (es) | 2011-12-16 | 2015-02-04 | Moderna Therapeutics Inc | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. |
| ES2799448T3 (es) | 2011-12-27 | 2020-12-17 | Amgen Europe Gmbh | Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-4-acetil-aminoisoindolina-1,3-diona |
| EP2834259A4 (de) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | Modifizierte polynukleotide |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| KR20150029678A (ko) | 2012-06-06 | 2015-03-18 | 바이오노르 이뮤노 에이에스 | 백신 |
| TWI690322B (zh) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| JP6359563B2 (ja) | 2013-01-14 | 2018-07-18 | デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ | ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 |
| EP2764866A1 (de) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Hemmer der nedd8-aktivierenden Enzyme |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| BR112015025252A2 (pt) | 2013-04-02 | 2017-07-18 | Celgene Corp | métodos e composições usando 4-amino-2-(2,6-dioxo-piperidina-3-il)-isoindolina-1,3-diona para tratamento e gestão de cânceres de sistema nervoso central |
| EP2801364A1 (de) * | 2013-05-07 | 2014-11-12 | Centre Hospitalier Universitaire Vaudois (CHUV) | Salmonellenstamm zur Verwendung bei der Behandlung und/oder Vorbeugung von Krebs |
| EP2815749A1 (de) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum |
| WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US20170165321A1 (en) | 2014-07-11 | 2017-06-15 | Bionor Immuno As | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) |
| WO2016177833A1 (en) | 2015-05-04 | 2016-11-10 | Bionor Immuno As | Dosage regimen for hiv vaccine |
| TWI727211B (zh) * | 2018-09-27 | 2021-05-11 | 大江生醫股份有限公司 | 紅菽草萃取物用於提升玻尿酸合成酶之基因表現量的用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2444713A1 (fr) | 1978-12-18 | 1980-07-18 | Pasteur Institut | Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant |
| AU633561B2 (en) | 1989-04-05 | 1993-02-04 | Peter Y. S. Fung | Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins |
| EP0621780A1 (de) | 1992-01-21 | 1994-11-02 | Immulogic Pharmaceutical Corporation | Verfahren zur anwendung von histaminderivaten als immunmodulatoren und in der immuntherapie |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5728385A (en) * | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| ES2339425T3 (es) | 1996-07-24 | 2010-05-20 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-il)-ftalimidas y -1-oxoisoindolinas sustituidas y procedimiento para reducir los niveles de tnf-alfa. |
| EP1361210B1 (de) | 1996-08-12 | 2008-12-24 | Celgene Corporation | Neue immunotherapeutische Mittel und deren Verwendung in der Reduzierung von Cytokinenspiegel |
| US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| CZ299253B6 (cs) | 1998-03-16 | 2008-05-28 | Celgene Corporation | Isoindolinový derivát, jeho použití pro výrobu léciva a farmaceutická kompozice tento derivát obsahující |
| CZ20013338A3 (cs) | 1999-03-18 | 2002-03-13 | Celgene Corporation | Substituované 1-oxo-a l,3-dioxoisoindoliny a jejich pouľití ve farmaceutických prostředcích pro sníľení koncentrací zánětlivých cytokinů |
| WO2001045750A1 (en) * | 1999-12-21 | 2001-06-28 | The Regents Of The University Of California | Method for preventing an anaphylactic reaction |
| AUPR030800A0 (en) * | 2000-09-22 | 2000-10-12 | Pharmalink International Limited | Immunomodulatory preparation |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030129161A1 (en) * | 2001-09-17 | 2003-07-10 | Hsien-Jue Chu | Interleukin-12 as a veterinary vaccine adjuvant |
| CA2482924A1 (en) * | 2002-04-19 | 2003-10-30 | Endocyte, Inc. | Adjuvant enhanced immunotherapy |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| EP2105136A3 (de) * | 2002-05-17 | 2010-01-27 | Celgene Corporation | Pharmazeutische Zusammensetzungen zur Behandlung von Krebs |
| CA2501940A1 (en) * | 2002-10-09 | 2004-04-22 | Tolerrx, Inc. | Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use |
| EP1897548B2 (de) * | 2003-02-28 | 2024-05-22 | The Johns Hopkins University | T-Zellenregulierung |
| EP1660126A1 (de) * | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonisten oder antagonisten des glucocorticoid-induzierten tumor-nekosefaktor-rezeptors (gitr) oder seiner liganden zur behandlung von immunstörungen, infektionen und krebs |
| US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
-
2006
- 2006-08-31 EP EP06824878A patent/EP1928492B1/de active Active
- 2006-08-31 RS RS20110194A patent/RS51840B/en unknown
- 2006-08-31 SI SI200631013T patent/SI1928492T1/sl unknown
- 2006-08-31 PL PL06824878T patent/PL1928492T3/pl unknown
- 2006-08-31 ES ES06824878T patent/ES2359162T3/es active Active
- 2006-08-31 DE DE602006020300T patent/DE602006020300D1/de active Active
- 2006-08-31 JP JP2008529318A patent/JP2009507030A/ja not_active Withdrawn
- 2006-08-31 AT AT06824878T patent/ATE499112T1/de active
- 2006-08-31 CA CA2621136A patent/CA2621136C/en not_active Expired - Fee Related
- 2006-08-31 EP EP11151126.7A patent/EP2301535B1/de active Active
- 2006-08-31 US US11/514,447 patent/US8715677B2/en not_active Expired - Fee Related
- 2006-08-31 WO PCT/US2006/034271 patent/WO2007028047A2/en active Application Filing
- 2006-08-31 DK DK06824878.0T patent/DK1928492T3/da active
- 2006-08-31 ES ES11151126.7T patent/ES2485316T3/es active Active
-
2011
- 2011-04-13 CY CY20111100376T patent/CY1112325T1/el unknown
- 2011-05-10 HR HR20110348T patent/HRP20110348T1/hr unknown
-
2012
- 2012-04-02 US US13/437,739 patent/US20120190110A1/en not_active Abandoned
-
2013
- 2013-07-03 JP JP2013140191A patent/JP5796040B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5796040B2 (ja) | 2015-10-21 |
| WO2007028047A3 (en) | 2007-06-14 |
| EP2301535A1 (de) | 2011-03-30 |
| US20120190110A1 (en) | 2012-07-26 |
| DE602006020300D1 (de) | 2011-04-07 |
| EP1928492B1 (de) | 2011-02-23 |
| ES2485316T3 (es) | 2014-08-13 |
| ES2359162T3 (es) | 2011-05-19 |
| CA2621136C (en) | 2014-10-14 |
| ATE499112T1 (de) | 2011-03-15 |
| JP2013241424A (ja) | 2013-12-05 |
| EP2301535B1 (de) | 2014-05-28 |
| PL1928492T3 (pl) | 2011-09-30 |
| RS51840B (en) | 2012-02-29 |
| EP1928492A2 (de) | 2008-06-11 |
| US8715677B2 (en) | 2014-05-06 |
| CA2621136A1 (en) | 2007-03-08 |
| SI1928492T1 (sl) | 2011-09-30 |
| CY1112325T1 (el) | 2015-12-09 |
| US20070048327A1 (en) | 2007-03-01 |
| JP2009507030A (ja) | 2009-02-19 |
| WO2007028047A2 (en) | 2007-03-08 |
| DK1928492T3 (da) | 2011-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110348T1 (hr) | Imunološke primjene imunomodulatornih spojeva za cjepivo i za liječenje infektivnih bolesti | |
| Slifka et al. | Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity | |
| Alam et al. | CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection | |
| JP2009507030A5 (de) | ||
| Christiansen et al. | Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery | |
| Yokokawa et al. | Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model | |
| DK1294893T3 (da) | Modifikation af hepatitis B-kerneantigen | |
| CY1112572T1 (el) | Εμβολια γριπης που περιλαμβανουν συνδυασμους σωματιδιακων ανοσοενισχυτικων και ανοσοδιεγερτες | |
| Richards et al. | Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans | |
| BG98523A (en) | Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b | |
| ATE527281T1 (de) | Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte | |
| SI2484375T1 (en) | A vaccine composition comprising a synthetic adjuvant | |
| DK0528859T3 (da) | Oral vaccine, som omfatter antigen knyttet til overfladen af røde blodlegemer | |
| DE60121136D1 (de) | Proteasom-influenzavirus-impfstoffzusammensetzung | |
| US20090304735A1 (en) | Immunogenic Compositions | |
| NZ545048A (en) | Chimeric antigens for breaking host tolerance to foreign antigens | |
| IL130075A0 (en) | A vaccine for eliciting an immune response to an antigen in an animal | |
| Wagstaffe et al. | Vaccinating for natural killer cell effector functions | |
| Van Hoeven et al. | A novel synthetic TLR-4 agonist adjuvant increases the protective response to a clinical-stage West Nile virus vaccine antigen in multiple formulations | |
| CY1110744T1 (el) | Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c | |
| Quattrocchi et al. | Co-inoculation of baculovirus and FMDV vaccine in mice, elicits very early protection against foot and mouth disease virus without interfering with long lasting immunity | |
| Julier et al. | Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses | |
| Aspord et al. | pDCs efficiently process synthetic long peptides to induce functional virus‐and tumour‐specific T‐cell responses | |
| ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
| Zhao et al. | Clearance of HBeAg and HBsAg of HBV in mice model by a recombinant HBV vaccine combined with GM-CSF and IFN-α as an effective therapeutic vaccine adjuvant |